SEARCH
You are in browse mode. You must login to use MEMORY

   Log in to start


From course:

CNS Pharmacology

» Start this Course
(Practice similar questions for free)
Question:

Dalfampridine

Author: Suzuki



Answer:

Dalfampridine, a potassium channel blocker administered orally, improves walking speeds vs placebo. It is the first drug approved for this use. Currently approved MS drugs are indicated to decrease relapse rates or in some cases to prevent accumulation of disability


0 / 5  (0 ratings)

1 answer(s) in total

Author

Suzuki
Suzuki